37 citations
,
April 2008 in “The Cochrane library” This study concluded that five-alpha-reductase inhibitors may reduce prostate cancer risk but could increase the risk of high-grade prostate cancer in men regularly screened for the disease.
2 citations
,
April 2021 in “Canadian Journal of Urology” This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.
2 citations
,
January 2017 in “Annals of Dermatology” Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.
January 2018 in “Surgical and Cosmetic Dermatology” This review provides an up-to-date analysis of the efficacy and safety of five-alpha reductase inhibitors, specifically finasteride and dutasteride, for treating benign prostatic hyperplasia and male androgenetic alopecia, highlighting their FDA approval history and current use.
4 citations
,
May 2019 in “The World Journal of Men's Health” This study found no significant increase in depression risk associated with taking five-alpha reductase inhibitors for benign prostatic hyperplasia or alopecia, although further studies are needed to confirm these findings.